Raw Material Supply Chain Security for Cell and Gene Therapies: Guidance and best practices from Rx-360 industry consortium
Cell therapies, including CAR-T and TCR-T, and gene therapies will offer transformative outcomes for challenging diseases.
The need for unmet treatment options and the promise of cell therapies and gene therapies has prompted regulatory agencies around the world to develop accelerated review pathways. Shortened development timelines in response to global demand has added to the challenges associated with producing these novel treatments.
Industry experts from Avantor and leading pharmaceutical organizations collaborated on guidance and best practices for raw material supply chain management in a recent report developed and released by Rx-360, a consortium of manufacturers and suppliers from the pharmaceutical and biotech industries focusing on enhancing the security and consistency of the global pharma supply chain.
From the small-scale bench to full commercial manufacturing, we enable our customers to reach the market with new treatments for patients, faster and safer. Learn more about our offering for biopharmaceutical manufacturing.